Etoposide

**Section:** 8. Immunomodulators and antineoplastics  8.2. Antineoplastics and supportive medicines  8.2.1. Cytotoxic medicines

**Indication**
Unspecified malignant neoplasms of ill-defined or unspecified sites

**INN**
Etoposide

**Medicine type**
Chemical agent

**List type**
Complementary

**Formulations**
- Parenteral > General injections > IV: 20 mg per mL in 5 mL ampoule
- Oral > Solid: 100 mg capsule

**EML status history**
- First added in 1984 (TRS 722)
- Changed in 2002 (TRS 914)
- Changed in 2007 (TRS 950)
- Changed in 2011 (TRS 965)
- Removed in 2015 (TRS 994)

**Sex**
All

**Age**
Adolescents and adults

**Therapeutic alternatives**
The recommendation is for this specific medicine

**Patent information**
- Patents have expired in most jurisdictions
- Read more about patents.

**Tags**
- Cancer

**Wikipedia**
- Etoposide

**DrugBank**
- Etoposide

**Summary of evidence and Expert Committee recommendations**

As part of the comprehensive review of cancer medicines undertaken by the Expert Committee in 2015, listing of etoposide was reviewed and specific indications for its use were recommended. Refer to the 2015 recommendation(s) for etoposide for more information.